AU1012588A - Method of treatment of central nervous system diseases such as alzheimer's disease and parkinson's disease and method of diagnosing alzheimer's disease - Google Patents

Method of treatment of central nervous system diseases such as alzheimer's disease and parkinson's disease and method of diagnosing alzheimer's disease

Info

Publication number
AU1012588A
AU1012588A AU10125/88A AU1012588A AU1012588A AU 1012588 A AU1012588 A AU 1012588A AU 10125/88 A AU10125/88 A AU 10125/88A AU 1012588 A AU1012588 A AU 1012588A AU 1012588 A AU1012588 A AU 1012588A
Authority
AU
Australia
Prior art keywords
disease
alzheimer
parkinson
treatment
nervous system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU10125/88A
Other versions
AU604820B2 (en
Inventor
Chaovanee Dr. Aroonsakul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AROONSAKUL C
Original Assignee
AROONSAKUL C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AROONSAKUL C filed Critical AROONSAKUL C
Priority to AU10125/88A priority Critical patent/AU604820B2/en
Publication of AU1012588A publication Critical patent/AU1012588A/en
Application granted granted Critical
Publication of AU604820B2 publication Critical patent/AU604820B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/61—Growth hormones [GH] (Somatotropin)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU10125/88A 1988-01-08 1988-01-08 Method of treatment of central nervous system diseases such as alzheimer's disease and parkinson's disease and method of diagnosing alzheimer's disease Ceased AU604820B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU10125/88A AU604820B2 (en) 1988-01-08 1988-01-08 Method of treatment of central nervous system diseases such as alzheimer's disease and parkinson's disease and method of diagnosing alzheimer's disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU10125/88A AU604820B2 (en) 1988-01-08 1988-01-08 Method of treatment of central nervous system diseases such as alzheimer's disease and parkinson's disease and method of diagnosing alzheimer's disease

Publications (2)

Publication Number Publication Date
AU1012588A true AU1012588A (en) 1989-07-13
AU604820B2 AU604820B2 (en) 1991-01-03

Family

ID=3701112

Family Applications (1)

Application Number Title Priority Date Filing Date
AU10125/88A Ceased AU604820B2 (en) 1988-01-08 1988-01-08 Method of treatment of central nervous system diseases such as alzheimer's disease and parkinson's disease and method of diagnosing alzheimer's disease

Country Status (1)

Country Link
AU (1) AU604820B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU633851B2 (en) * 1988-09-15 1993-02-11 Microbiological Research Authority Pharmaceutical compositions for eliciting an immunostimulant effect

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107328A0 (en) * 1992-10-20 1994-01-25 Btg Pharma Corp Composition for ameliorating muscle weakness/wasting in an hiv-1 infected patient

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU633851B2 (en) * 1988-09-15 1993-02-11 Microbiological Research Authority Pharmaceutical compositions for eliciting an immunostimulant effect

Also Published As

Publication number Publication date
AU604820B2 (en) 1991-01-03

Similar Documents

Publication Publication Date Title
US5037384B2 (en) Method and apparatus for the treatment of complicated retinal detachments
AU674894C (en) Treatment of conditions and disease
AU2830097A (en) Therapeutic method for treatment of alzheimer's disease
AU8392291A (en) Tachykinin agonists for treatment of alzheimer's disease
AU6905391A (en) Methods and compositions for the treatment of hodgkin's disease
AU5292290A (en) Diagnostic method for alzheimer's disease: examination of non-neural tissue
IL105216A0 (en) Method and kit for the diagnosis of alzheimer's disease
AU6747887A (en) Treatment of skin disorders
EP0331620A3 (en) Agent for the treatment of parkinson's disease
AU4759390A (en) Method of medical treatment of alzheimer's disease
AU1790988A (en) Phosphoethanolamine for treatment of alzheimer's disease
AU7556994A (en) Methods for the diagnosis of alzheimer's disease
EP1011644A4 (en) Methods and apparatus for treatment of parkinson's disease
EP0506893A4 (en) Diagnosis and treatment of diseases
AU2101288A (en) Taliscanin and other aristolactams for treating neurological disorders, parkinson's disease, alzheimer disease and impotence
AU3861989A (en) Method for the treatment and the diagnosis of coronary heart disease
AU1831195A (en) Methods and compositions for treatment and diagnosis of alzheimer disease and other disorders
AU7394387A (en) Sialosylcholesterol, process for its preparation, and drug for treating diseases of nervous system
AU1012588A (en) Method of treatment of central nervous system diseases such as alzheimer's disease and parkinson's disease and method of diagnosing alzheimer's disease
EP0457671A3 (en) Dipyridamide for the treatment of diseases of the central or peripheral nervous system
AU1807592A (en) New combination preparation for treatment of parkinson's disease
EP0486584A4 (en) Dopaminergic neurotrophic factor for treatment of parkinson's disease
AU608865B2 (en) Treatment of cerebral disorders
CS413888A1 (en) Method of 3-methyl-2-pentene-4-in-1-ol's cis-isomer production
GB8828185D0 (en) Improved medicine for treatment & prevention of stress & nervous disorders

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired